OMAHA, Neb. (WOWT) - The FDA is cracking down on off brand weight loss products similar to Ozempic. GLP-1 drugs for weight loss like Wegovy or Zepbound were previously in a shortage.

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

A former head of the US Food and Drug Administration cut his body fat in half using GLP-1 drugs. In his book, he compares the ...

In this week’s edition of InnovationRx, we look at the FDA's new rules on Covid-19 vaccines, Novartis’s acquisition strategy, ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

The injectable drug Ozempic is shown Saturday ... 503A and 503B, based on the FDA regulations that govern their operations. The latter is impacted by the ruling, according to industry experts.

Though Noom says the approach complies with FDA regulations allowing personalized ... to increase manufacturing capacity of Wegovy and Ozempic, a GLP-1 approved for patients with Type 2 diabetes.

The end of copycat weight-loss drugs When the Food and Drug Administration ... loss drugs Ozempic and Wegovy. There are still ways that companies can get around the compounding regulations and ...

Since Ozempic hit the ... against our biology”. The FDA, his prior workplace, sets guidelines around food safety, he points out. But, he asks, why there are no regulations protecting the ...